WNK2 and non-small cell lung carcinoma: (2020) demonstrated that in NSCLC resistant to crizotinib, ROS1 rearrangements lead to an upregulation of PD-L1 expression via the mitogen-activated protein kinase kinase (MEK) - extracellular signal-regulated kinases (ERK) signaling pathway (18).